Phase III APPLY-PNH and APPOINT-PNH trials investigate iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria, 48-week data: Phillip Scheinberg, ASH 2023
Watch Time: 13 mins
The 48-week data from the phase III APPLY-PNH and APPOINT-PNH trials investigates iptacopan, a first oral proximal complement inhibitor targeting factor B, in patients with paroxysmal nocturnal haemoglobinuria. We met with Dr Phillip Scheinberg (Hospital A Beneficência Portuguesa, São Paulo, Brazil) to discuss the data, and he reports the proportion of patients with clinical breakthrough […]